The daily GLP-1 pill Foundayo: already in the US and the UK, now recommended for the EU
What changed
The EMA's committee for human medicines recommended authorising Foundayo (orforglipron, Eli Lilly) in the European Union: a GLP-1 tablet taken once a day, at any time, with or without food, for weight management and type 2 diabetes in adults. In the two weight studies, with 4,740 adults, people lost about 5–11% of their weight after 72 weeks, depending on the dose, compared with 2–2.5% on placebo. The FDA approved Foundayo in the US in April 2026, and the UK's MHRA authorised it on 10 August 2026.
What it means for you
- 1In the EU this is a recommendation, not yet an authorisation. The European Commission usually decides within about two months; after that, each country sets the price.
- 2In the UK it is available on private prescription. It is not on the NHS while NICE assesses it.
- 3If your current treatment works well, there is nothing to change. New options are a conversation with your doctor.
What does not change
Injectable treatments stay the same. The most common side effects reported with Foundayo come from the same family: nausea, vomiting and diarrhoea, mostly when the dose goes up.
Sources
- EMA — New oral GLP-1 medicine for weight management and type 2 diabetes, 16 October 2026ema.europa.eu · accessed 16 Nov
- MHRA — UK first in Europe to authorise orforglipron, 10 August 2026gov.uk · accessed 16 Nov
- AJMC — FDA approves Lilly's oral GLP-1 orforglipron for obesity, 1 April 2026ajmc.com · accessed 16 Nov